West Pharmaceutical Services (WST) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were $702.1 million, down 6.9% year-over-year, with organic net sales declining 5.9% and sequential improvement from Q1.

• Diluted EPS was $1.51, down from $2.06 in Q2 2023; adjusted diluted EPS was $1.52, down from $2.11.

• Customer destocking continued to impact results, but management expects stronger performance in H2 and a return to organic growth in Q4, led by biologics.

• The company remains confident in its long-term growth strategy, supported by capital expansion projects and a strong position in high-value products and biologics.

• Investments made for COVID-19 are being repurposed to address new opportunities, with ongoing expansions in Grand Rapids and Dublin to support growth in injection devices and drugs for diabetes and obesity.

Financial highlights

• Q2 2024 net sales were $702.1 million, representing a 5.9% organic sales decline year-over-year.

• Gross profit margin for Q2 2024 was 32.8%, down from 38.7% in Q2 2023.

• Adjusted operating profit margin was 18.0%, down from 24.5% in Q2 2023; adjusted diluted EPS declined 28%.

• Operating cash flow for the first six months was $283.2 million, down 7.8% year-over-year; free cash flow was $92.4 million, down 38.3%.

• Cash and cash equivalents at June 30, 2024, were $446.2 million, down from $853.9 million at year-end 2023.

Outlook and guidance

• Full-year 2024 net sales guidance lowered to $2.87–$2.90 billion from $3.00–$3.025 billion.

• Organic net sales expected to decrease 1%-2% for 2024, versus prior guidance of 2%-3% growth.

• Adjusted diluted EPS guidance reduced to $6.35–$6.65 from $7.63–$7.88.

• Capital spending for 2024 expected to be $375 million, up from previous estimate of $350 million.

• Return to organic growth anticipated in Q4 2024, with confidence in resuming 7%-9% long-term growth in 2025.